Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iratumumab (Medarex)
- Development stage
- Discontinued
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Iratumumab (MDX-060) is a fully human IgG1 monoclonal antibody directed against CD30 (TNFRSF8), a cell surface antigen highly expressed on Reed-Sternberg cells in Hodgkin lymphoma and neoplastic cells in anaplastic large cell lymphoma (ALCL). Developed by Medarex in collaboration with Bristol Myers Squibb, iratumumab was designed to induce antitumor activity through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and signal transduction inhibition. While it demonstrated a manageable safety profile in Phase I/II clinical trials for relapsed or refractory CD30-positive lymphomas, its clinical development was ultimately discontinued as it did not show sufficient monotherapy efficacy to compete with emerging therapies like the antibody-drug conjugate brentuximab vedotin.
- Other names
- anti-CD30 monoclonal antibodyanti-CD-30 monoclonal antibodyanti-CD 30 monoclonal antibody
02
Targets
CD30 (CD30 antigen)
Beyond the preview
Go deeper on iratumumab (Medarex).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iratumumab (Medarex).